REGNNASDAQ— Regeneron Pharmaceuticals Inc Price & Analysis

Regeneron Pharmaceuticals Inc

HEALTHCARE — BIOTECHNOLOGY

$805.02

-$14.07-1.72%

Market Cap: $84.33B; Large Cap
P/E Ratio: 20.25; Fwd: 14.51
EPS (TTM): $40.44
Div. Yield: 0.45%

Technical Summary

RSI (14)58.05Neutral

SMA (50)$791.33Bullish

SMA (200)$734.73Bullish

MACD8.1745Bullish

Bollinger$709.48 – $823.03Mid

Stochastic88.25Overbought

Theo Outlook

Regeneron Pharmaceuticals Inc is a biotechnology company headquartered in Tarrytown, New York, that studies cytokine and tyrosine kinase receptors. For the trailing twelve months ending June 30, 2026, the company reported revenue of $15.53 billion, a profit margin of 27.9 percent, earnings per share of $40.44, and a market capitalization of $84.33 billion.

Bull case: Quarterly revenue grew 16.7 percent year over year, return on equity reached 14 percent, and the forward price-to-earnings ratio stood at 14.51. Bear case: Quarterly earnings declined 4.5 percent year over year, the price-to-sales ratio was 5.43, and the company carried a beta of 0.153.

Main risks include regulatory changes in biotechnology and competition in drug development. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Fundamental Snapshot

Revenue: $15.53B
EBITDA: $4.70B
Gross Profit: $6.91B
Operating Margin: 33.1%
Profit Margin: 27.9%
ROE: 14.0%
Book Value: $316.11
Beta: 0.15
52-Wk High: $859.34
52-Wk Low: $572.99
Volume: 524.68K
PEG Ratio: 1.32

Frequently Asked Questions

What does Regeneron do?

Regeneron Pharmaceuticals Inc is a biotechnology company headquartered in Tarrytown, New York. It originally focused on neurotrophic factors and later expanded into the study of cytokine and tyrosine kinase receptors.

Where does Regeneron's revenue come from?

For the trailing twelve months ending June 30, 2026, Regeneron reported revenue of $15.53 billion. Revenue per share for the same period was $150.31.

How does Regeneron compete?

Regeneron reported an operating margin of 33.1 percent and a return on assets of 6.53 percent for the trailing twelve months ending June 30, 2026. Its price-to-book ratio stood at 2.603 over the same period.

What are the main risks for Regeneron?

Regeneron faces risks from quarterly earnings that declined 4.5 percent year over year as of June 30, 2026. The company also operates in a sector with a beta of 0.153.

How is Regeneron valued?

As of the latest data, Regeneron trades at a trailing price-to-earnings ratio of 20.25, a forward price-to-earnings ratio of 14.51, and a price-to-sales ratio of 5.43. Its book value per share is $316.11.